Andrew Dorr
- Oncology top 10%
- PARP inhibition in cancer therapy 6
- Cancer Treatment and Pharmacology 4
- Genetics top 10%
- Molecular Biology top 10%
- Protein Kinase Regulation and GTPase Signaling 5
- PI3K/AKT/mTOR signaling in cancer 3
- Melanoma and MAPK Pathways 3
- Hematology top 10%
- Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment 5
-
- Prostate Cancer Treatment and Research 5
-
- Radiopharmaceutical Chemistry and Applications 3
- Co-authors
- Richard S. GearyJon HolmlundT. Jesse KwohJohn NemunaitisBranimir I. ŠikićCasey CunninghamGeorge A. FisherJoanne Halsey
- Cited by
- OncologyGeneticsMolecular Biology
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Andrew Dorr
34 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 74
- Oncology 356
- Genetics 124
- Molecular Biology 737
- Hematology 110
- Reproductive Medicine 60
Countries citing papers authored by Andrew Dorr
This map shows the geographic impact of Andrew Dorr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Dorr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Dorr more than expected).
Fields of papers citing papers by Andrew Dorr
This network shows the impact of papers produced by Andrew Dorr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Dorr. The network helps show where Andrew Dorr may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andrew Dorr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2023 | 0 | |
| 3 | 2021 | 1 | |
| 4 | 2021 | 8 | |
| 5 | 2020 | 7 | |
| 6 | 2015 | 95 | |
| 7 | 2014 | 1 | |
| 8 | 2013 | 1 | |
| 9 | 2009 | 21 | |
| 10 | 2009 | 4 | |
| 11 | [Guideline for gynecological malignant tumors 2004--primary complex therapy in operable stages of malignant tumors of vulva]. | 2004 | 1 |
| 12 | 2004 | 56 | |
| 13 | 2003 | 17 | |
| 14 | 2003 | 55 | |
| 15 | A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. | 2002 | 99 |
| 16 | 2001 | 71 | |
| 17 | 1994 | 35 | |
| 18 | 1990 | 2 | |
| 19 | 1987 | 2 | |
| 20 | 1971 | 1 |
About Andrew Dorr
Andrew Dorr is a scholar working on Reproductive Medicine, Oncology, Hematology, Cancer Research and Obstetrics and Gynecology, having authored 37 papers that have together received 1.0k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (6 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), Ovarian cancer diagnosis and treatment (5 papers), Prostate Cancer Treatment and Research (5 papers), Cancer Treatment and Pharmacology (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Melanoma and MAPK Pathways (3 papers). The work is most often cited by research in Oncology (356 citations), Genetics (124 citations), Molecular Biology (737 citations), Hematology (110 citations) and Reproductive Medicine (60 citations). Andrew Dorr has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Richard S. Geary, Jon Holmlund, T. Jesse Kwoh, John Nemunaitis, Branimir I. Šikić, Casey Cunningham, George A. Fisher, Joanne Halsey, Joan H. Schiller and Elizabeth A. Eisenhauer. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Cancer, Molecular Cancer Therapeutics and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.